Source: Investing.com ↗

Exelixis stock falls as FDA extends zanzalintinib review

|

Translation unavailable. Please try again.

Original report

Read the original report on Investing.com ↗

Recommended markets

No specific asset was identified in this report; browse live USDT reference pairs.

Browse markets →

USDC/USDT

$1.00

-0.02%

BTC/USDT

$85,845.26

-0.34%

ETH/USDT

$2,733.57

-0.55%

ZEC/USDT

$1,624.79

+8.07%

XRP/USDT

$1.60

+3.88%